Login
Join for Free

All Posts

Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

GMP Audit Checklist 2026: The Essential Guide for Risk-Based Audits

Master your GMP Audit Checklist with a practical, risk-based approach to pharmaceutical self-inspections. Explore five essential audit steps, FDA’s six-system model, GMP documentation and evidence sampling, audit findings, CAPA tracking, and effectiveness verification to strengthen compliance and inspection readiness.
  • Audit, Blog, FDA, Quality Assurance, Regulatory
FDA and EMA regulatory review illustration showing medical plausibility assessments, scientific checklists, a medicine vial, and rare disease patients
Picture of Mahtab Shardi

Mahtab Shardi

Orphan Drug Designation in 2026: FDA and EMA Eligibility Criteria

Discover how orphan drug designation works in 2026. Compare FDA and EMA eligibility criteria, rare disease prevalence thresholds, scientific evidence requirements, and regulatory incentives. Learn what pharmaceutical sponsors need to prepare for successful regulatory submissions
  • Blog, Quality Assurance, Regulatory
Quality assurance specialist reviewing a Certificate of Suitability with digital verification icons in a pharmaceutical manufacturing facility
Picture of Mahtab Shardi

Mahtab Shardi

CEP certificate in pharma: What QA Must Verify in 2026

Learn how QA teams verify EDQM certificates, assess API suppliers, and prepare for GMP inspections. This guide explains CEP 2.0 updates, impurity controls, and essential records that help maintain regulatory compliance and inspection readiness across pharmaceutical manufacturing operations.
  • Blog, Quality Assurance, Regulatory
CAPA and Deviation Review in Pharma
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

GMP Inspection Readiness : A Proven Audit Guide in 2026

GMP inspection readiness means showing that your pharmaceutical quality systems work every day. This practical guide walks QA, QC and site leaders through a five-step, risk-based preparation framework, with priority evidence to review, mock inspection tips, CAPA guidance and answers to common inspection questions.
  • Blog, FDA, Quality Assurance, Quality Control, Regulatory
Pharmaceutical Team at Vial Filling Line
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

GMP Training Matrix in 2026: How to Build an Audit-Ready, Role-Based Training System

Learn how to build a GMP training matrix that links pharma team roles to SOPs, records competency evidence, tracks retraining, and supports inspection readiness.
  • Blog, FDA, Quality Control, Regulatory
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

Universities vs Pharmuni in 2026: Faster Pharma Career Readiness

Universities provide formal degrees, research depth and academic credibility. Pharmuni adds faster pharma-specific upskilling, assessments, Career Paths, CV tools and job-readiness support. Here is how the two models differ—and when using both makes sense.
  • Blog, FDA, Quality Control, Regulatory
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

Innopharma Education vs Pharmuni in 2026: The Ultimate Career Game-Changer?

Innopharma Education offers structured, accredited life-science programmes with formal academic pathways and career support. Pharmuni is a lighter, self-paced pharma career ecosystem combining courses, assessments, Career Paths, CV tools, and job matching. This guide compares where each model fits best.
  • Blog, FDA, Quality Control, Regulatory
ISPE Training vs Pharmuni: Courses, Cost & Careers
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

ISPE Training vs Pharmuni in 2026: Deep Technical Training or a Full Pharma Career System?

ISPE offers deep specialist pharmaceutical training and respected technical certificate programs. Pharmuni combines 50+ pharma courses with free assessments, Career Paths, CV tools, competency benchmarking, and job matching. Here is where each platform fits best.
  • Blog, FDA, Quality Control, Regulatory
Pharmaceutical infographic showing risks in the generic drug approval process, including CMC gaps, facility readiness, and review delays.
Picture of Mahtab Shardi

Mahtab Shardi

ANDA Application in 2026: FDA Requirements, Submission Process and GMP Inspection Readiness

Preparing an ANDA requires more than a complete dossier. This article explains FDA submission requirements, bioequivalence expectations, CMC consistency, facility readiness, and common review delays, helping regulatory and quality teams understand what can slow generic drug approval.
  • Blog, Quality Assurance, Quality Control, Regulatory, Validation
Scientist, drug manufacturing line, and quality documentation representing CMC regulatory strategy and pharmaceutical development controls.
Picture of Mahtab Shardi

Mahtab Shardi

Regulatory Strategy in Pharma in 2026: From Drug Development to GMP Inspection Readiness

Effective regulatory planning connects drug development, CMC, submissions, manufacturing, and lifecycle obligations. This article explains how regulatory teams can reduce compliance gaps, prepare for inspections, manage post-approval changes, and make better decisions across the pharmaceutical product lifecycle.
  • Blog, Quality Assurance, Quality Control, Regulatory, Validation